| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Monday, March 06, 2023 2:15:57 PM
Your point 2 is over the top. The reality is, the asset of DCVax, in and of itself has demonstrated value and the market typically reflects that value. More importantly, the events of spoofing happened on key days when such news is announced and sets the level of market interest. The spoofing destroyed market confidence and interest at that time. Delaying a sense of validation. There were huge numbers of shares traded on those days. Had the share price gone to where it should have gone and stayed, there would be plenty of all of the things you claim now are not there. In fact, by spoofing, and we will find out the people behind it and the reasons most likely given, they will have a lot more evidence than we have now. Spoofing is not “trading”, someone is sending a false message to deceive the market. So no motive, no reason justifies it. But we will learn more in discovery.
More importantly however, the likely price point it should have gone to but for spoofing, and the price differential, will be set and those were grossly illegal acts. The value of the company is not about the lawsuit. The lawsuit will be about getting to the bottom of the stock manipulation that we have seen go on for years now, and the persons behind it WILL be exposed. Ending or settling the case should NOT be the top agenda item, especially because it costs the company nothing to continue. The focus should be on exposure and if more illegality is found, likely further defendants and hopefully also prosecution. What the SEC and US Attorneys have not yet discovered may likely yet be discovered through this civil suit.
Honestly, I do not care when they win it. But I expect them to win.
More importantly however, the likely price point it should have gone to but for spoofing, and the price differential, will be set and those were grossly illegal acts. The value of the company is not about the lawsuit. The lawsuit will be about getting to the bottom of the stock manipulation that we have seen go on for years now, and the persons behind it WILL be exposed. Ending or settling the case should NOT be the top agenda item, especially because it costs the company nothing to continue. The focus should be on exposure and if more illegality is found, likely further defendants and hopefully also prosecution. What the SEC and US Attorneys have not yet discovered may likely yet be discovered through this civil suit.
Honestly, I do not care when they win it. But I expect them to win.
Bullish
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
